Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 113.27 0.68% 0.76
ALXN closed up 0.68 percent on Friday, January 17, 2020, on 1.12 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Jan 30
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical ALXN trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Bearish Engulfing Bearish 0.68%
Stochastic Sell Signal Bearish 0.68%
Upper Bollinger Band Walk Strength 0.68%
Weak + Overbought Other 0.68%
BB Squeeze Ended Range Expansion 0.68%
Weak, Overbought and Reversal Signs Reversal 0.68%
Overbought Stochastic Strength 0.68%
Down 3 Days in a Row Weakness 0.68%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Medicine Biopharmaceutical Medical Specialties Organ Systems Healthcare Providers Paroxysmal Nocturnal Hemoglobinuria Metabolic Disorders Acquired Hemolytic Anemia Inflammatory Disorders Myasthenia Gravis Alexion Pharmaceuticals Atypical Hemolytic Uremic Syndrome Genetic Disease Hemolytic Uremic Syndrome Kidney Transplant Renal Transplant

Is ALXN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 141.86
52 Week Low 94.59
Average Volume 1,683,250
200-Day Moving Average 115.43
50-Day Moving Average 110.32
20-Day Moving Average 109.81
10-Day Moving Average 110.73
Average True Range 3.00
ADX 17.3
+DI 20.24
-DI 14.92
Chandelier Exit (Long, 3 ATRs ) 105.36
Chandelier Exit (Short, 3 ATRs ) 113.56
Upper Bollinger Band 114.36
Lower Bollinger Band 105.26
Percent B (%b) 0.88
BandWidth 8.29
MACD Line 0.76
MACD Signal Line 0.20
MACD Histogram 0.5617
Fundamentals Value
Market Cap 25.28 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 49.03
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 116.09
Resistance 3 (R3) 116.14 115.24 115.62
Resistance 2 (R2) 115.24 114.53 115.22 115.46
Resistance 1 (R1) 114.26 114.08 114.75 114.21 115.31
Pivot Point 113.36 113.36 113.61 113.34 113.36
Support 1 (S1) 112.38 112.65 112.87 112.33 111.23
Support 2 (S2) 111.48 112.20 111.46 111.08
Support 3 (S3) 110.50 111.48 110.92
Support 4 (S4) 110.45